"High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)"@en . "Kuipers, J. E" . "Coenen, E. A." . "[1D71434D9F06]" . . "Baruchel, A." . "High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)"@en . . "http://www.ncbi.nlm.nih.gov/pubmed/21045196" . "Cloos, J." . "1"^^ . "0006-4971" . . . "Balgobind, BV" . "Pieters, R." . "8"^^ . "High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)" . . . . "Reinhardt, D." . "Blood" . . "de Haas, V." . "Pediatric mixed-lineage leukemia (MLL)-rearranged acute monoblastic leukemia with t(9;11)(p22;q23) has a favorable outcome compared with other MLL-rearranged AML. The biologic background for this difference remains unknown. Therefore, we compared gene expression profiles (GEPs; Affymetrix HGU133 + 2.0) of 26 t(9; 11)(p22;q23) patients with 42 other MLL-rearranged AML. patients to identify differentially expressed genes. IGSF4, a cell-cell adhesion molecule, was found to be highly expressed in t(9; 11)(p22; q23) patients, which was confirmed by real-time quantitative polymerase chain reaction and Western blot. IGSF4 expression within t(9;11)(p22;q23) patients was 4.9 times greater in French-American-British morphology classification (FAB)-M5 versus other FAB-types (P = .001). Methylation status investigation showed that high IGSF4-expressing t(9;11)(p22;q23) patients with FAB-M5 have no promoter hypermethylation, whereas all other cases do. Cell-line incubation with demethylating agent decitabine resulted in promoter demethylation and increased expression of IGSF4. Down-regulation of IGSF4 by siRNA did not affect proliferation or drug sensitivity. In a cohort of 79 MLL-rearranged AML cases, we show significant better overall survival for cases with high IGSF4 expression (5-year overall survival 0.70 vs 0.37, P = .03) In conclusion, we identified IGSF4 overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit. (Blood.2011;117(3):928-935)" . "Zwaan, CM" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "RIV/00064203:_____/11:6949" . "Meyer, C." . . "000286426300025" . "acute lymphoblastic-leukemia; drug sensitivity; oncology-group; in-vivo; cell; children; resistance; childhood; tslc1; aml"@en . "Marschalek, R." . "117" . "van den Heuvel-Eibrink, MM" . . "Pediatric mixed-lineage leukemia (MLL)-rearranged acute monoblastic leukemia with t(9;11)(p22;q23) has a favorable outcome compared with other MLL-rearranged AML. The biologic background for this difference remains unknown. Therefore, we compared gene expression profiles (GEPs; Affymetrix HGU133 + 2.0) of 26 t(9; 11)(p22;q23) patients with 42 other MLL-rearranged AML. patients to identify differentially expressed genes. IGSF4, a cell-cell adhesion molecule, was found to be highly expressed in t(9; 11)(p22; q23) patients, which was confirmed by real-time quantitative polymerase chain reaction and Western blot. IGSF4 expression within t(9;11)(p22;q23) patients was 4.9 times greater in French-American-British morphology classification (FAB)-M5 versus other FAB-types (P = .001). Methylation status investigation showed that high IGSF4-expressing t(9;11)(p22;q23) patients with FAB-M5 have no promoter hypermethylation, whereas all other cases do. Cell-line incubation with demethylating agent decitabine resulted in promoter demethylation and increased expression of IGSF4. Down-regulation of IGSF4 by siRNA did not affect proliferation or drug sensitivity. In a cohort of 79 MLL-rearranged AML cases, we show significant better overall survival for cases with high IGSF4 expression (5-year overall survival 0.70 vs 0.37, P = .03) In conclusion, we identified IGSF4 overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit. (Blood.2011;117(3):928-935)"@en . . "den Boer, M. L." . . "3" . "I" . . . "Danen-van Oorschot, A. A." . . "Kaspers, GJL" . . . . . "202017" . "de Bont, ESJM" . . . "17"^^ . . "High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)" . "RIV/00064203:_____/11:6949!RIV12-MZ0-00064203" . "Star\u00FD, Jan" .